Human papillomavirus vaccine recombinant bivalent - EyeGene

Drug Profile

Human papillomavirus vaccine recombinant bivalent - EyeGene

Alternative Names: EG-HPV; HPV VLP vaccine - Eyegene; Human papillomavirus (types 16 and 18) L1 virus-like particle vaccine - EyeGene

Latest Information Update: 31 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EyeGene
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer; Human papillomavirus infections; Penile cancer

Most Recent Events

  • 01 Jan 2013 Phase-I clinical trials in Human papillomavirus infections in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top